Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis.
Sánchez A, Brun LR, Salerni H, Costanzo PR, González D, Bagur A, Oliveri B, Zanchetta MB, Farías V, Maffei L, Premrou V, Mansur JL, Larroudé MS, Sarli MA, Rey P, Ulla MR, Pavlove MM, Karlsbrum S, Brance ML. Sánchez A, et al. Among authors: ulla mr. J Osteoporos. 2016;2016:8738959. doi: 10.1155/2016/8738959. Epub 2016 Aug 8. J Osteoporos. 2016. PMID: 27579211 Free PMC article.
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A. Langdahl BL, et al. Among authors: ulla mr. Lancet. 2017 Sep 30;390(10102):1585-1594. doi: 10.1016/S0140-6736(17)31613-6. Epub 2017 Jul 26. Lancet. 2017. PMID: 28755782
Clinical and molecular studies related to bone metabolism in patients with congenital adrenal hyperplasia.
Martín S, Muñoz L, Pérez A, Sobrero G, Picotto G, Ochetti M, Carpentieri A, Silvano L, de Barboza GD, Signorino M, Rupérez C, Bertolotto P, Ulla MR, Pellizas C, Montesinos M, Tolosa de Talamoni N, Miras M. Martín S, et al. Among authors: ulla mr. J Pediatr Endocrinol Metab. 2014 Nov;27(11-12):1161-6. doi: 10.1515/jpem-2014-0104. J Pediatr Endocrinol Metab. 2014. PMID: 25026125
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.
25 results